Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

1 hour ago 1

Jonathan Ponciano, The Motley Fool

Mon, March 23, 2026 astatine 12:37 PM CDT 3 min read

Sarissa Capital Management established a caller presumption successful Biohaven Ltd. (NYSE:BHVN) during the 4th quarter, acquiring 513,184 shares worthy $5.79 cardinal astatine quarter’s end, according to a February 17, 2026, SEC filing.

According to an SEC filing dated February 17, 2026, Sarissa Capital Management initiated a caller involvement successful Biohaven during the 4th quarter, purchasing 513,184 shares. The quarter-end valuation of the caller presumption stood astatine $5.79 million, reflecting the full worth of shares held aft the trade.

This was a caller presumption for Sarissa, bringing Biohaven Ltd. to 2.6% of reportable U.S. equity AUM.
Top holdings aft the filing:
- NASDAQ:INVA: $56.29 cardinal (25.3% of AUM)
- NASDAQ:IRWD: $53.65 cardinal (24.1% of AUM)
- NASDAQ:NBIX: $43.00 cardinal (19.3% of AUM)
- NASDAQ:CYTK: $25.18 cardinal (11.3% of AUM)
- NASDAQ:AMRN: $23.35 cardinal (10.5% of AUM)
As of Monday, Biohaven shares were priced astatine $8.90, down a staggering 70% implicit the past twelvemonth and good underperforming the S&P 500, which is alternatively up astir 15% successful the aforesaid period.

Metric

Value

Price (as of Monday)	$8.90
Market Capitalization	$1.3 billion
Net Income (TTM)	($738.8 million)

Biohaven develops therapies for neurological and immunoscience diseases; presently focused connected clinical-stage cause candidates.
The steadfast operates a biopharmaceutical concern exemplary centered connected probe and development, with aboriginal gross expected from licensing and commercialization of proprietary treatments.
It targets healthcare providers and patients affected by neurological and immune-related conditions arsenic superior customers.

Biohaven Ltd. is simply a clinical-stage biotechnology institution specializing successful the improvement of innovative therapies for neurological and immunoscience disorders. With a absorption connected advancing caller cause candidates, the institution leverages proprietary probe to code unmet aesculapian needs. Biohaven aims to found a competitory presumption done its committedness to technological innovation and targeted therapeutic development.

Biohaven contiguous is simply a reset story. The FDA rejection of troriluzole and a drawstring of disappointing proceedings updates crushed sentiment, but the underlying strategy hasn’t disappeared. Management is present concentrating resources connected a smaller acceptable of late-stage programs, including its degrader level and a Phase 2 obesity campaigner with information expected aboriginal this year. That benignant of absorption matters erstwhile superior is tight.

The equilibrium expanse is inactive holding up amended than you mightiness expect for a institution successful this position. Biohaven ended 2025 with astir $322 cardinal successful currency and raised different $178.9 cardinal aft year-end, buying it clip to get done cardinal objective readouts. Meanwhile, its obesity programme conscionable completed enrollment, mounting up a imaginable catalyst successful the 2nd fractional of 2026 .

Put this successful discourse of the portfolio, and the logic becomes clearer. This is simply a money that already leans heavy into clinical-stage biotech, truthful adding a distressed sanction fits the playbook. Upcoming information and execution volition substance astir next.

Read Entire Article